The Week in Review: Oct 26 – Nov 2, 2018

Friday, Nov 2, 2018 News Recap: Report on the Pacific AIDS Network (PAN) 2018 Fall Conference in Kelowna The Pacific AIDS Network held its annual Fall Conference and AGM October 30-31 in Kelowna. HepCBC attended this year for the first time as a Full Member, due to changes in the PAN Constitution and Bylaws. New Bylaws included: PAN no longer requires its hepatitis C organizational members to offer HIV-related services. Aging and Viral Hepatitis ...

Potential markers identified for early detection and prevention of liver cancer

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure—but now a study offers hope of early detection, and targets for new treatments. Published in Frontiers in Cell and Developmental Biology, the results show a dramatic increase in expression of sugar-burning 'glycolytic' enzymes in precancerous cirrhotic livers. This increase is associated with a sign

The Week in Review: Oct 19 – Oct 26, 2018

Friday, Oct 26, 2018 News Recap: HepCBC Annual General Meeting INVITATION TO ALL We invite everyone to have a say in the direction of HepCBC, a BC-wide patient advocacy group confronting Viral Hepatitis since 1996, through participation in our upcoming Annual General Meeting (AGM) – either in person or online! 7th Annual Liver Forum 2018 in Vancouver! On October 19th, Volunteers Douglas Laird and Cheryl Reitz of HepCBC attended the exciting 7th ...

Interleukin IL-22, a new target to inhibit the progression of liver disease

Montreal, October 26, 2018 - Naglaa Shoukry, Ph. D., and her team have made a significant breakthrough in their research aiming to limit the progression of liver disease. They have characterized the mechanisms of action of type 3 inflammatory cytokines that are produced by the cells of the immune system, which result in a progression of hepatic scarring known as fibrosis. These research efforts have identified new potential targets to inhibit the progressi

Does Cannabis Use Reduce Cirrhosis Risk in HCV Patients?

In an observation of a large pool of patients with hepatitis C virus (HCV), cannabis users had a lower prevalence of liver cirrhosis, more favorable health status at hospital discharge, and lower total health care costs than non-users. Adeyinka Adejumo, lead author of the study and graduate student at the University of Massachusetts Intercampus Program in Biomedical Engineering and Biotechnology, and colleagues indicated the findings add to a relationship

The Week in Review: January 26 – February 2, 2018

Friday, February 2, 2018 News Recap: From the Uh-Oh Department: HCV Can Reactivate with Treatment of Non-hepatic Cancer. Hepatitis C virus (HCV) reactivation occurred in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment. Compensation Update: Compensation – New Update for 86-90 Late Claims. If you or a family member received a blood transfusion o...

SVR for HCV with no advanced liver disease greatly reduces mortality risk

Patients with hepatitis C without advanced liver disease who achieved sustained virologic response with direct-acting antiviral therapy had significantly reduced all-cause mortality rates compared with both treated patients who did not achieve SVR and untreated patients, according to a recently published data. “These data strongly support a clinically significant benefit of DAA treatment in patients without clinically apparent advanced liver disease and e

Smoking reduces survival after liver cancer diagnosis for people with viral hepatitis

People with viral hepatitis who smoked were three times more likely to die after being diagnosed with liver cancer (hepatocellular carcinoma, HCC), according to a study of Swiss patients published in Liver International. Whereas non-smokers lived for a median of 3.2 years after diagnosis, smokers died after a median of 18 months. Smoking had a similar impact on survival in those who did not receive curative treatment in the form of liver resection (surger

The Week in Review: December 8 – December 15, 2017

Friday, December 15, 2017 News Recap: 8 updates on liver transplantation outcomes for 2017: Over the past year, researchers and physicians have reported changes among the leading indications on the liver waitlist and improvements in transplantation outcomes. In this article, Healio.com/Hepatology presents recent reports on waitlist mortality risks, improved pediatric liver transplantation outcomes, and the positive effects of HCV treatment on transpl...

Liver Damage Worse in Women With HBV/HCV Coinfection, Risky Drinking

Coinfection with hepatitis B and C virus (HBV/HCV) combined with risky alcohol consumption enhances liver damage mechanisms to a greater extent in women than in men, according to a recent study in PLoS One. Hepatitis infection and risky drinking are major risk factors for liver disease, and coinfection with both HBV and HCV is more likely to progress to cirrhosis than single infections. Pooled data from 2 national surveys in Italy allowed the estimation o